Acurx Pharmaceuticals (ACXP) Total Current Liabilities (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Total Current Liabilities for 7 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 9.31% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (up 9.31% YoY), and the FY2025 full-year result was $2.4 million, down 25.35% from the prior year.
• Total Current Liabilities improved to $2.8 million in Q2 2026 per ACXP's latest filing, from $2.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $3.3 million in Q3 2024 and bottomed at $473879.0 in Q2 2022.
• Historically, Total Current Liabilities has averaged $2.4 million across 5 years, with a median of $2.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities plunged 75.3% in 2022, then surged 537.17% in 2023.
• Over 5 years, Total Current Liabilities stood at $2.1 million in 2022, then soared by 47.57% to $3.0 million in 2023, then climbed by 6.59% to $3.2 million in 2024, then fell by 25.35% to $2.4 million in 2025, then advanced by 17.01% to $2.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.8 million, $2.5 million, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.